<DOC>
	<DOCNO>NCT00350415</DOCNO>
	<brief_summary>A Double-blind , Randomized , 6-week , Parallel-group Design Clinical trial ass Safety Efficacy Asacol 4.8 g/day ( 800 mg mesalamine tablet ) versus Asacol 2.4 g/day ( 400 mg mesalamine tablet ) Treatment Moderately Active Ulcerative Colitis ( ASCEND III ) .</brief_summary>
	<brief_title>A Double Blind Study Treatment Acute Ulcerative Colitis</brief_title>
	<detailed_description>This double-blind , randomize , multi-center , multi-national , active-control study patient experience moderately active flare UC . Patients randomly assign receive either Asacol 2.4 g/day ( 400 mg tablet ) Asacol 4.8 g/day ( 800 mg tablet ) 6 week . Patients randomize one 2 treatment group 1:1 ratio . The objective study evaluate safety efficacy Asacol 4.8 g/day ( 800 mg tablet ) compare Asacol 2.4 g/day ( 400 mg tablet ) patient population . Following successful screening , patient randomize one two treatment arm . Patients evaluate 6 week treatment interim visit 3 week .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients 1875 year confirm diagnosis moderately active flare ulcerative colitis . Female patient need postmenopausal use adequate contraception . Patients isolated proctitis Patients comorbidities investigative commercialize treatment confound interpretation study result compromise patient ' safety trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>ulcerative colitis , inflammatory bowel disease</keyword>
</DOC>